Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral

This article was originally published in The Pink Sheet Daily

Executive Summary

The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.

You may also be interested in...



With A Drug On The Fast Track, Chimerix Aims To Go Public

Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.

Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute

The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.

Merck Steps Up As AiCuris’ First Development Partner

Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel